Showing results (31-40 of 67) with videos related to

Sort By:
Pageof 7
International Journal of Cancer|November 6, 2021
Pazopanib with 5-FU and oxaliplatin as first line therapy in advanced gastric cancer: A randomized phase-II study-The PaFLO trial. A study of the Arbeitsgemeinschaft Internistische Onkologie AIO-STO-0510Anica Högner, Salah-Eddin Al-Batran, Jens T Siveke, et al.
European Journal of Cancer (Oxford, England : 1990)|February 24, 2022
FOLFIRI plus ramucirumab versus paclitaxel plus ramucirumab as second-line therapy for patients with advanced or metastatic gastroesophageal adenocarcinoma with or without prior docetaxel - results from the phase II RAMIRIS Study of the German Gastric Cancer Study Group at AIOSylvie Lorenzen, Peter Thuss-Patience, Claudia Pauligk, et al.
Nutrition and Cancer|September 26, 2017
Importance of Pancreatic Enzyme Replacement Therapy after Surgery of Cancer of the Esophagus or the Esophagogastric JunctionThomas Kiefer, Dorothea Krahl, Kathrin Osthoff, et al.
International Journal of Cancer|May 21, 2021
Trastuzumab in combination with 5-fluorouracil, leucovorin, oxaliplatin and docetaxel as perioperative treatment for patients with human epidermal growth factor receptor 2-positive locally advanced esophagogastric adenocarcinoma: A phase II trial of the Arbeitsgemeinschaft Internistische Onkologie Gastric Cancer Study GroupRalf-Dieter Hofheinz, Susanne Hegewisch-Becker, Volker Kunzmann, et al.
European Journal of Cancer (Oxford, England : 1990)|February 20, 2015
Lapatinib versus lapatinib plus capecitabine as second-line treatment in human epidermal growth factor receptor 2-amplified metastatic gastro-oesophageal cancer: a randomised phase II trial of the Arbeitsgemeinschaft Internistische OnkologieSylvie Lorenzen, Jorge Riera Knorrenschild, Georg-Martin Haag, et al.
Journal of Cancer Research and Clinical Oncology|March 13, 2017
HER2 testing in gastric cancer: results of a German expert meetingFlorian Lordick, Salah-Eddin Al-Batran, Manfred Dietel, et al.
JAMA Network Open|January 23, 2024
Ramucirumab, Avelumab, and Paclitaxel as Second-Line Treatment in Esophagogastric Adenocarcinoma: The Phase 2 RAP (AIO-STO-0218) Nonrandomized Controlled TrialPeter Thuss-Patience, Anica Högner, Eray Goekkurt, et al.
European Journal of Cancer (Oxford, England : 1990)|March 5, 2018
Perioperative chemotherapy with or without epidermal growth factor receptor blockade in unselected patients with locally advanced oesophagogastric adenocarcinoma: Randomized phase II study with advanced biomarker program of the German Cancer Society (AIO/CAO STO-0801)Michael Stahl, Annett Maderer, Florian Lordick, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|January 8, 2022
Efficacy and safety of trifluridine/tipiracil in older and younger patients with metastatic gastric or gastroesophageal junction cancer: subgroup analysis of a randomized phase 3 study (TAGS)Kohei Shitara, Toshihiko Doi, Hisashi Hosaka, et al.
BMC Cancer|May 26, 2019
EORTC-1203-GITCG - the "INNOVATION"-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: a randomized phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer groupAnna Dorothea Wagner, Heike I Grabsch, Murielle Mauer, et al.
Pageof 7